Background/Aims: Brain natriuretic peptide (BNP) is secreted by cardiomyocytes under stretch condition. High blood levels are associated with decreased patient survival in heart failure patients and in hemodialysis (HD) patients. We report the monthly BNP change in the first months of HD therapy in incident patients and its relationship with fluid removal and cardiac history (CH). Methods: All patients starting HD therapy in our unit from May 2008 to December 2012 were retrospectively analyzed. Every month (M1 to M6), BNP was assessed before a midweek dialysis session. CH, monthly pre- and postdialysis blood pressure, and postdialysis body weight were collected. Results: A total of 236 patients were included in the analysis. The median BNP at HD start was 593 (175-1,433) pg/mL, with a significant difference between CH- and CH+ patients (291 vs. 731 pg/mL, p < 0.0001). Mortality was significantly higher in patients in the higher BNP tertile. BNP decreased significantly between M1 and M2 and then plateaued. The BNP change between M1 and M2 and between M1 and M6 was significantly correlated with the initial fluid removal. Applying stepwise multiple regression, the BNP change between M1 and M2 was significantly and independently related to fluid removal. The BNP level at M6 was also related to patient survival. Conclusions: We confirm that in incident HD patients, BNP level is related to fluid excess and cardiac status. The BNP decrease in the first months of HD therapy is related to fluid excess correction. BNP appears as an important tool to evaluate hydration status correction after HD onset.

Keywords:
Hemodialysis, Incident patients, Fluid overload, Brain natriuretic peptide, Survival
1.
Joffy S, Rosner MH: Natriuretic peptides in ESRD. Am J Kidney Dis 2005;46:1-10.
2.
Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
3.
Zoccali C, Mallamaci F, Benedetto F, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino L; Creed Investigators: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001;12:1508-1515.
4.
Agarwal R: B-type natriuretic peptide is not a volume marker among patients on hemodialysis. Nephrol Dial Transplant 2013;28:3082-3089.
5.
Chazot C, Vo-Van C, Deleaval P, Lorriaux C, Hurot JM, Mayor B, Jean G: Predialysis systolic blood pressure evolution in incident hemodialysis patients: effects of the dry weight method and prognostic value. Blood Purif 2012;33:275-283.
6.
Charra B, Laurent G, Chazot C, Calemard E, Terrat JC, Vanel T, Jean G, Ruffet M: Clinical assessment of dry weight. Nephrol Dial Transplant 1996;11:16-19.
7.
Essig M, Escoubet B, de Zuttere D, Blanchet F, Arnoult F, Dupuis E, Michel C, Mignon F, Mentre F, Clerici C, Vrtovsnik F: Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant 2008;23:239-248.
8.
Chazot C, Vo-Van C, Lorriaux C, Mayor B, Hurot JM, Deleaval P, Zaoui E, Jean G: Brain natriuretic peptide in incident hemodialysis patients: effects of fluid removal, cardiac status and prognostic value. World Congress of Nephrology, Cape Town, 2015.
9.
Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-2017.
10.
Francis GS, Felker GM, Tang WH: A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 2016;67:330-337.
11.
Tapolyai M, Faludi M, Reti V, Lengvarszky Z, Szarvas T, Fulop T, Beko G, Berta K: Volume estimation in dialysis patients: the concordance of brain-type natriuretic peptide measurements and bioimpedance values. Hemodial Int 2013;17:406-412.
12.
Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V: Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant 2012;27:2404-2410.
13.
Wizemann V, Wabel P, Chamney P, Zaluska W, Moissl U, Rode C, Malecka-Masalska T, Marcelli D: The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009;24:1574-1579.
14.
Sivalingam M, Vilar E, Mathavakkannan S, Farrington K: The role of natriuretic peptides in volume assessment and mortality prediction in haemodialysis patients. BMC Nephrol 2015;16:218.
15.
Celik G, Silinou E, Vo-Van C, Jean G, Chazot C: Plasma BNP, a useful marker of fluid overload in hospitalized hemodialysis patients. Hemodial Int 2012;16:47-52.
16.
Ohashi Y, Saito A, Yamazaki K, Tai R, Matsukiyo T, Aikawa A, Sakai K: Brain natriuretic peptide and body fluid composition in patients with chronic kidney disease: a cross-sectional study to evaluate the relationship between volume overload and malnutrition. Cardiorenal Med 2016;6:337-346.
17.
Agarwal R, Alborzi P, Satyan S, Light RP: Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009;53:500-507.
18.
Agarwal R: Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 2010;56:512-517.
19.
van de Pol AC, Frenken LA, Moret K, Baumgarten R, van der Sande FM, Beerenhout CM, Kooman JP, Leunissen KM: An evaluation of blood volume changes during ultrafiltration pulses and natriuretic peptides in the assessment of dry weight in hemodialysis patients. Hemodial Int 2007;11:51-61.
20.
De Mauri A, Bellomo G, Navino C, David P, Chiarinotti D, Capurro F, Brustia M, De Maria M, Ruva CE, Ciardi L, De Leo M: Plasma B-type natriuretic peptide in dialyzed patients: marker of cardiovascular disease or link to plasma refilling. J Nephrol 2011;24:507-514.
21.
Bednarek-Skublewska A, Zaluska W, Ksiazek A: The relationship between serum level of N-terminal pro-B-type natriuretic peptide and nutritional status, and inflammation in chronic hemodialysis patients. Clin Nephrol 2010;73:14-20.
22.
Arneson TJ, Liu J, Qiu Y, Gilbertson DT, Foley RN, Collins AJ: Hospital treatment for fluid overload in the Medicare hemodialysis population. Clin J Am Soc Nephrol 2010;5:1054-1063.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.